These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 18598745

  • 1. Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone.
    Li C, Cui J, Wang C, Wang J, Li Y, Zhang L, Zhang L, Guo W, Wang Y.
    Int J Pharm; 2008 Oct 01; 362(1-2):60-6. PubMed ID: 18598745
    [Abstract] [Full Text] [Related]

  • 2. Ni2+-mediated mitoxantrone encapsulation: improved efficacy of fast release formulation.
    Cui J, Li C, Wang L, Wang C, Yang H, Li Y, Zhang L, Zhang L, Guo W, Liang M.
    Int J Pharm; 2009 Feb 23; 368(1-2):24-30. PubMed ID: 18973800
    [Abstract] [Full Text] [Related]

  • 3. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy.
    Li C, Cui J, Wang C, Li Y, Zhang H, Wang J, Li Y, Zhang L, Zhang L, Guo W, Wang Y.
    Eur J Pharm Biopharm; 2008 Oct 23; 70(2):657-65. PubMed ID: 18582570
    [Abstract] [Full Text] [Related]

  • 4. Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release.
    Li C, Cui J, Li Y, Wang C, Li Y, Zhang L, Zhang L, Guo W, Wang J, Zhang H, Hao Y, Wang Y.
    Eur J Pharm Sci; 2008 Aug 07; 34(4-5):333-44. PubMed ID: 18573336
    [Abstract] [Full Text] [Related]

  • 5. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J, Li C, Guo W, Li Y, Wang C, Zhang L, Zhang L, Hao Y, Wang Y.
    J Control Release; 2007 Apr 02; 118(2):204-15. PubMed ID: 17239468
    [Abstract] [Full Text] [Related]

  • 6. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
    Hao YL, Deng YJ, Chen Y, Wang KZ, Hao AJ, Zhang Y.
    J Pharm Pharmacol; 2005 Oct 02; 57(10):1279-87. PubMed ID: 16259756
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pegylated liposomal mitoxantrone is more therapeutically active than mitoxantrone in L1210 ascitic tumor and exhibits dose-dependent activity saturation effect.
    Li C, Zhao X, Deng C, Wang C, Wei N, Cui J.
    Int J Pharm; 2014 Jan 02; 460(1-2):165-72. PubMed ID: 24148664
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Encapsulation of vinorelbine into cholesterol-polyethylene glycol coated vesicles: drug loading and pharmacokinetic studies.
    Li C, Cui J, Wang C, Zhang L, Xiu X, Li Y, Wei N, Li Y, Zhang L.
    J Pharm Pharmacol; 2011 Mar 02; 63(3):376-84. PubMed ID: 21749385
    [Abstract] [Full Text] [Related]

  • 11. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
    Chow TH, Lin YY, Hwang JJ, Wang HE, Tseng YL, Wang SJ, Liu RS, Lin WJ, Yang CS, Ting G.
    Anticancer Res; 2009 Jun 02; 29(6):2111-20. PubMed ID: 19528471
    [Abstract] [Full Text] [Related]

  • 12. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C, Wang C, Yang H, Zhao X, Wei N, Cui J.
    J Pharm Pharmacol; 2012 Mar 02; 64(3):372-82. PubMed ID: 22309269
    [Abstract] [Full Text] [Related]

  • 13. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone.
    Lim HJ, Masin D, Madden TD, Bally MB.
    J Pharmacol Exp Ther; 1997 Apr 02; 281(1):566-73. PubMed ID: 9103545
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.
    Suzuki R, Takizawa T, Kuwata Y, Mutoh M, Ishiguro N, Utoguchi N, Shinohara A, Eriguchi M, Yanagie H, Maruyama K.
    Int J Pharm; 2008 Jan 04; 346(1-2):143-50. PubMed ID: 17640835
    [Abstract] [Full Text] [Related]

  • 16. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
    Hong RL, Huang CJ, Tseng YL, Pang VF, Chen ST, Liu JJ, Chang FH.
    Clin Cancer Res; 1999 Nov 04; 5(11):3645-52. PubMed ID: 10589782
    [Abstract] [Full Text] [Related]

  • 17. Kupffer cells do not play a role in governing the efficacy of liposomal mitoxantrone used to treat a tumor model designed to assess drug delivery to liver.
    Lim HJ, Parr MJ, Masin D, McIntosh NL, Madden TD, Zhang G, Johnstone S, Bally MB.
    Clin Cancer Res; 2000 Nov 04; 6(11):4449-60. PubMed ID: 11106266
    [Abstract] [Full Text] [Related]

  • 18. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
    Lim HJ, Masin D, McIntosh NL, Madden TD, Bally MB.
    J Pharmacol Exp Ther; 2000 Jan 04; 292(1):337-45. PubMed ID: 10604968
    [Abstract] [Full Text] [Related]

  • 19. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
    Gabizon AA, Tzemach D, Horowitz AT, Shmeeda H, Yeh J, Zalipsky S.
    Clin Cancer Res; 2006 Mar 15; 12(6):1913-20. PubMed ID: 16551877
    [Abstract] [Full Text] [Related]

  • 20. [Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice].
    Chen T, Hou SX, Wang YY, Zhang WS, Chen DH.
    Yao Xue Xue Bao; 2006 Dec 15; 41(12):1170-5. PubMed ID: 17290615
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.